Search Results for "Xarelto Vs Pradaxa"

06:13 EDT 22nd September 2014 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa

Columbus, OH (PRWEB) July 27, 2014 The Institute of Safe Medication Practices (ISMP) Found that the number of serious adverse events such as Xarelto bleeding side-effects reported after the use of ...

Pradaxa, Xarelto, Eliquis: NOACs' Reversal a Key?

(MedPage Today) -- The new oral anticoagulants, or NOACs -- dabigatran (Pradaxa), rivaroxaban (Xarelto), and Eliquis (apixaban) -- are touted for their safety, efficacy, and ease of use, but they have...

Pradaxa MDL Court Orders Establishment of Qualified Settlement Fund, Notes Rottenstein Law Group LLP

The firm currently represents patients who allege that they have suffered serious side effects from use of anticoagulants Pradaxa and Xarelto. Rockville Centre, NY (PRWEB) August 19, 2014 The Rottens...

Pradaxa Available in the UK for DVT, PE

Boehringer Ingelheim has announced that Pradaxa will be commercially available in the UK for the treatment of DVT and PE

Xarelto Lawsuit News: The Rottenstein Law Group Comments on New Study that Shows Xarelto® Surpassing Pradaxa in the Number of Reported Injuries

The firm currently represents patients who allege that they have suffered serious side effects from use of Xarelto. Rockville Centre, NY (PRWEB) June 26, 2014 The Rottenstein Law Group LLP, a nationa...

Bayer plans 3 new trials to support expanded use of stroke prevention drug Xarelto

FRANKFURT (Reuters) - Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines. Xarelto, which...

Physician Views: Can Bayer deliver on its Xarelto bullishness?

Recently added to the BioPortfolio report store, Physician Views: Can Bayer deliver on its Xarelto bullishness? is a new report from Firstword published on 2014-03-09. This report is available from ...

Bayer Submits Xarelto for DVT, PE Approval in Japan

Bayer HealthCare’s oral anticoagulant Xarelto (rivaroxaban) has been submitted to the Japanese Ministry of Health, Labor and Welfare (MHLW) for marketing authori

Matching PubMed Articles

Perioperative management and therapy of bleeding complications.

The new oral anticoagulants directly inhibit either thrombin (Dabigatran, Pradaxa®,) or activated Factor X (rivaroxaban, Xarelto®, and apixaban, Eliquis®) and have been approved for thromboprophyla...

Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

A sensitive and accurate liquid chromatography method with mass spectrometry detection was developed and validated for the quantification of dabigatran (Pradaxa(®)) and rivaroxaban (Xarelto(®)). (13...

Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice.

To explore and detail clinical experiences of dabigatran, a novel anticoagulant, after it became available in New Zealand in July 2011.

{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.

In October 2011, DTB reviewed the use of dabigatran, the first new oral anticoagulant licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillatio...

Rivaroxaban: A Review of Its Use in the Treatment of Deep Vein Thrombosis or Pulmonary Embolism and the Prevention of Recurrent Venous Thromboembolism.

Rivaroxaban (Xarelto(®)), an oral direct factor Xa inhibitor, is approved for the initial treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent D...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement